Targeting SLC3a2 with Oligonucleotides to Overcome Cisplatin Resistance in HNSCC

Overview

This research focuses on the development of a novel antisense oligonucleotide (ASO) sequence designed to target the mRNA sequence of a protein called SLC3A2 implicated in Head and Neck Squamous Cell Carcinoma (HNSCC). The primary goal of this is DNA based therapy is to hinder the production of SLC3A2 by degrading its mRNA, disrupting protein synthesis, and making cancer cells more responsive to chemotherapy. The study is distinct in its use of an ASO sequence optimization algorithm, aiming to minimize unintended effects. The research employs a comprehensive approach, integrating bioinformatic analysis, gene activity studies, and experimental validation. The initial hypothesis was that examining genetic activity in patient tumor samples and cisplatin-resistant cells would reveal genes related to amino acid metabolism, serving as targets for ASOs to sensitize cancer cells to cisplatin. Additionally, it was hypothesized that using ASOs to halt SLC3A2 in cisplatin resistant head and neck cancer cells will increase oxidation and reduce metabolic activity. The results confirm a significant increase in oxidative substances in treated cells, indicating the impact on stress. Moreover, elevated levels of SLC3A2 and another protein, SLC7A5, in HNSCC patient samples underscore the importance of targeting these proteins. Using ASOs appears promising for overcoming cisplatin resistance in HNSCC, offering potential for improved treatment outcomes and transforming the approach to cancer treatment by preventing protein synthesis through mRNA degradation.

Competition history

• AJAS 2025 Category not listed

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Browse more like this

• AJAS None projects
• Every AJAS 2025 project